Primary Prophylaxis of Gastric Varix Bleed

• Status: Completed
• Trial end date: 2009-01-01
• Target enrollment: 0
• Participant gender: All

Summary

In patients who have never bled from gastric varix (GOV2 and IGV1), cyanoacrylate injection will be better than both beta-blocker therapy and no treatment in prevention of gastric variceal bleed. The investigators conducted a randomized controlled trial in patients with gastric varix (GOV2 and IGV1) who never bled before, to study the efficacy of treatment with cyanoacrylate injection versus beta-blocker versus no treatment in prevention of first bleed from gastric varices.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Govind Ballabh Pant Hospital
• Treatments: Adrenergic beta-Antagonists; Propranolol

Criteria

Inclusion Criteria:

• Patients with GOV2 with eradicated esophageal varix or IGV1, who had never bled from gastric varix were included.

Exclusion Criteria:

• Only esophageal varix, GOV1 with GOV2, acute bleed or past history of bleed from gastric varix, contraindications to beta-blocker therapy and cyanoacrylate injection.

• Prior injection of cyanoacrylate or sclerotherapy or variceal ligation or transjugular intrahepatic portosystemic shunt or balloon-occluded retrograde transvenous obliteration or balloon-occluded endoscopic injection sclerotherapy of gastric varix for prevention of bleeding from GV

• Patients already on beta-blocker or nitrates

• Undetermined origin of bleeding from esophageal varix or gastric varix

• Hepatic encephalopathy grade III/IV

• Hepatorenal syndrome

• Hepatocellular carcinoma

• Presence of deep jaundice (serum bilirubin > 10 mg/dl)

• Uremia

• Cerebrovascular accident

• Cardiorespiratory failure

• Pregnancy and patients not giving informed consent for endoscopic procedures